Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2008 for pSivida Limited (referred to as "Eyepoint, Inc." in the request metadata, but identified as pSivida Limited in the filing). The company is a global drug delivery firm focused on the biomedical sector. Effective for the quarter ended September 30, 2007, the company changed its primary basis of accounting from Australian equivalents to International Financial Reporting Standards (A-IFRS) to U.S. GAAP. The company is currently proposing to reincorporate in the United States, subject to shareholder and court approval.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2008 | Nine Months Ended Mar 31, 2008 | Balance Sheet (Mar 31, 2008) |
|---|---|---|---|
| Total Revenues | $542,000 | $773,000 | N/A |
| Net Loss | $(5,501,000) | $(12,091,000) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $18,175,000 |
| Total Assets | N/A | N/A | $115,866,000 |
| Total Liabilities | N/A | N/A | $26,704,000 |
| Stockholders' Equity | N/A | N/A | $89,162,000 |
| Accumulated Deficit | N/A | N/A | $(160,958,000) |
Revenue Breakdown (Nine Months 2008): Collaborative research and development ($681,000) and Royalty income ($92,000).
Operating Expenses (Nine Months 2008): Research and development ($12,022,000) and Selling, general and administrative ($8,609,000).
Cash Flow (Nine Months 2008): Net cash used in operating activities was $(2,703,000); net cash provided by financing activities was $18,387,000.
Material Changes vs. Prior Period
- Revenue: For the three months ended March 31, 2008, revenue increased 47% to $542,000 from $369,000 in the prior year period, driven primarily by $426,000 recognized from an amended collaboration agreement with Alimera Sciences. For the nine months, revenue decreased 48% to $773,000 from $1,483,000, primarily due to a $671,000 reduction in royalty income from Bausch & Lomb.
- Net Loss: The net loss for the three months improved significantly to $(5.5) million from $(12.2) million in the prior year. For the nine months, the net loss improved to $(12.1) million from $(43.3) million. These improvements were largely due to a $7.2 million gain from the change in fair value of derivative liabilities and the absence of a $12.1 million loss on extinguishment of debt recorded in the prior year.
- Operating Expenses: Research and development expenses decreased 30% for the quarter and 29% for the nine months, primarily due to reduced amortization of intangible assets following a $45.3 million impairment write-down in June 2007 and personnel reductions. Selling, general, and administrative expenses increased 72% for the quarter due to legal fees related to reincorporation and collaboration agreements.
- Liquidity: Cash and cash equivalents increased from $2.7 million at June 30, 2007, to $18.2 million at March 31, 2008, bolstered by a $12.0 million cash payment from Alimera and proceeds from a July 2007 stock offering.
Guidance, Outlook, and Risks
- Outlook: Management believes current cash resources, combined with expected payments from Pfizer and Alimera, are sufficient to fund operations through at least June 30, 2010. The company expects to recognize approximately $2.5 million per quarter from the Alimera agreement through December 2009.
- Reincorporation: The company announced a proposal to reincorporate in the United States in mid-2008. If not implemented, the independent auditor may resign, potentially leading to delisting from NASDAQ and the ASX.
- Risks:
- Capital Dependence: Future funding depends on collaboration payments from Pfizer and Alimera. Failure to receive these payments could require additional capital raises on unfavorable terms.
- License Termination: Key licensees (Pfizer, Bausch & Lomb, Alimera) have rights to terminate agreements, which could halt product development.
- Derivative Liabilities: The company has significant derivative liabilities ($2.3 million) related to warrants denominated in Australian dollars. Fluctuations in the company's share price significantly impact the fair value of these liabilities and net income.
- Going Concern: While the company currently believes it can continue as a going concern, this is contingent on receiving expected collaboration payments.
- Unusual Items: The company recorded a $7.2 million gain from the change in fair value of derivatives for the nine months ended March 31, 2008, primarily due to a decrease in the market price of its ordinary shares. Additionally, a $1.5 million promissory note from the sale of a former subsidiary (AION) is overdue and in default.
Investor Verification Checklist
- Verify the status and timeline of the proposed U.S. reincorporation and its impact on the independent auditor relationship.
- Confirm the receipt of scheduled payments from Alimera Sciences and Pfizer, as future liquidity is heavily dependent on these collaborations.
- Monitor the company's share price volatility, as it directly impacts the valuation of derivative liabilities and reported net income.
- Review the status of the overdue $1.5 million promissory note from GEM Global Yield Fund and any legal actions taken.
- Assess the risk of delisting from NASDAQ if the minimum bid price requirement ($1.00 per ADS) is not met by June 24, 2008.
- Validate the assumptions used in the revenue recognition of the Alimera agreement, specifically the performance period and milestone triggers.